Sandoz Strikes $500m Deal For GSK Cephalosporins
Deal To Acquire Cephalosporins Business Reinforces Position In Antibiotics
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
You may also be interested in...
Plus recent deals involving AbbVie/Caribou, Sanofi/i2O, Merck & Co./Starpharma, Protalix/SarcoMed, Targovax/Papyrus, Medivir/Ubiquigent, Eton/Azurity
Sandoz has announced joint plans with the Austrian government to invest over €150m in antibiotics manufacturing.
Recruiting generics firms to the AMR Industry Alliance is a key area of focus for the group as part of its efforts to cover a greater proportion of the global supply of antimicrobials, according to the Alliance’s latest report.